NPPA fixes price of 45 medicine packs
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has fixed the price of 45 formulation packs including those used for treating cancer, epilepsy, heartburn, eczema and bacterial infections."NPPA has fixed / revised the prices in respect of 45 formulation packs under Drug Prices Control Order (DPCO) 2013," the regulator said in a notification on its website.The companies whose...
Login or Register to read the full article
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has fixed the price of 45 formulation packs including those used for treating cancer, epilepsy, heartburn, eczema and bacterial infections.
"NPPA has fixed / revised the prices in respect of 45 formulation packs under Drug Prices Control Order (DPCO) 2013," the regulator said in a notification on its website.
The companies whose drugs are included for price fixation includes drug majors such as erstwhile Ranbaxy (now Sun Pharmaceutical Industries), Torrent Pharmaceuticals, Abbott Healthcare, Glenmark and Cadila Healthcare, it added.
"The manufacturer or marketing company not complying with the retail prices and conditions specified in notes herein above from the date of this order/notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955," NPPA said.
NPPA's mandate is to fix/ revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
"NPPA has fixed / revised the prices in respect of 45 formulation packs under Drug Prices Control Order (DPCO) 2013," the regulator said in a notification on its website.
The companies whose drugs are included for price fixation includes drug majors such as erstwhile Ranbaxy (now Sun Pharmaceutical Industries), Torrent Pharmaceuticals, Abbott Healthcare, Glenmark and Cadila Healthcare, it added.
"The manufacturer or marketing company not complying with the retail prices and conditions specified in notes herein above from the date of this order/notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955," NPPA said.
NPPA's mandate is to fix/ revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd